GREY:ATBPF - Post by User
Comment by
MrMugsyon Dec 04, 2020 1:34pm
194 Views
Post# 32038248
RE:RE:RE:Updates from Dan
RE:RE:RE:Updates from DanPragmatist wrote: I suspect the CEO was a tad imprecise in his email. From the latest MD&A regarding current studies:
"They are being conducted in tranches to enable a timely start
to Phase III clinical trials. Short range studies are expected to conclude in calendar Q2 2021, enabling the commencement
of the 12-week Phase III efficacy trials. Long range studies are expected to conclude in calendar Q4 2021, enabling the
commencement of 24-week Phase III GI safety trials."
I do recall Dan saying the studies will finish at different times, going out to the end of 2021. I assumed the only study requred for enabling (FDA meeting and the go-head from them) was the one due in Q4 2020 - toxicity study. Any chance that's correct? With the others to follow and to be provided to FDA as they are completed?